Background The safety of observing small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs) remains under debate. Methods This was a multicentre retrospective study of patients with small incidental NF-Pan-NETs. Survival of patients who underwent upfront surgery versus active surveillance was compared. The risk of death was matched with that in the healthy population. The excess hazard rate and probability of a normal lifespan (NLP) were calculated. Propensity score matching (PSM) with a 1 : 1 ratio was used to minimize the risk of selection bias. Results Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) were observed. The excess hazard rate for the entire cohort was quantifiable as 0.04 (95 per cent c.i. 0 to 0.08) deaths per 1000 persons per year, and the NLP was 99.7 per cent. Patients in the active surveillance group were older (median age 65 versus 58 years; P < 0.001), and more often had co-morbidity (45.3 versus 24.8 per cent; P = 0.001), and smaller tumours (median 12 versus 13 mm; P < 0.001), less frequently located in the pancreatic body-tail (59.5 versus 69.6 per cent; P = 0.008, 59.3 versus 73.9 per cent; P = 0.001). Median follow-up was longer for patients who underwent upfront surgery (5.6 versus 2.7 years; P < 0.001). After PSM, 118 patients per group were included. The excess hazard rates were 0.2 and 0.9 deaths per 1000 persons per year (P = 0.020) for patients in the active surveillance and upfront surgery groups respectively. Corresponding NLPs were 99.9 and 99.5 per cent respectively (P = 0.011). Conclusion Active surveillance of small incidental NF-Pan-NETs is a reasonable alternative to resection.To aim was to evaluate whether a watchful strategy increased mortality risk compared with surgery. The study included 507 patients with small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs). Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) had active surveillance. Active surveillance for small incidental NF-Pan-NETs can be considered safe because it did not increase the background risk of death.Lay summary Neuroendocrine tumours are rare tumours which are most often found in the lungs, gastrointestinal tract and pancreas. They can be divided in tumours which produce and do not produce hormones. The latter are called non-functioning tumours. This study focused on non-functioning neuroendocrine tumours of the pancreas. If these are small, they can either be surgically removed or observed. Pancreatic surgery can lead to severe surgical complications. Observation is somewhat contra-intuitive in oncology as both doctors and patients may fear that the time window to successfully treat the tumour can be missed. In this study the authors reported on a large group of patients. Patients in both groups had very good survival. Both strategies are reasonable and should be discussed with patients.

Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours

Ricci, Claudio;Partelli, Stefano;Landoni, Luca;Savegnago, Giulia;Fontana, Michele;Tamburrino, Domenico;Deiro, Giacomo;Bassi, Claudio;Salvia, Roberto;Falconi, Massimo;
2022-01-01

Abstract

Background The safety of observing small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs) remains under debate. Methods This was a multicentre retrospective study of patients with small incidental NF-Pan-NETs. Survival of patients who underwent upfront surgery versus active surveillance was compared. The risk of death was matched with that in the healthy population. The excess hazard rate and probability of a normal lifespan (NLP) were calculated. Propensity score matching (PSM) with a 1 : 1 ratio was used to minimize the risk of selection bias. Results Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) were observed. The excess hazard rate for the entire cohort was quantifiable as 0.04 (95 per cent c.i. 0 to 0.08) deaths per 1000 persons per year, and the NLP was 99.7 per cent. Patients in the active surveillance group were older (median age 65 versus 58 years; P < 0.001), and more often had co-morbidity (45.3 versus 24.8 per cent; P = 0.001), and smaller tumours (median 12 versus 13 mm; P < 0.001), less frequently located in the pancreatic body-tail (59.5 versus 69.6 per cent; P = 0.008, 59.3 versus 73.9 per cent; P = 0.001). Median follow-up was longer for patients who underwent upfront surgery (5.6 versus 2.7 years; P < 0.001). After PSM, 118 patients per group were included. The excess hazard rates were 0.2 and 0.9 deaths per 1000 persons per year (P = 0.020) for patients in the active surveillance and upfront surgery groups respectively. Corresponding NLPs were 99.9 and 99.5 per cent respectively (P = 0.011). Conclusion Active surveillance of small incidental NF-Pan-NETs is a reasonable alternative to resection.To aim was to evaluate whether a watchful strategy increased mortality risk compared with surgery. The study included 507 patients with small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs). Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) had active surveillance. Active surveillance for small incidental NF-Pan-NETs can be considered safe because it did not increase the background risk of death.Lay summary Neuroendocrine tumours are rare tumours which are most often found in the lungs, gastrointestinal tract and pancreas. They can be divided in tumours which produce and do not produce hormones. The latter are called non-functioning tumours. This study focused on non-functioning neuroendocrine tumours of the pancreas. If these are small, they can either be surgically removed or observed. Pancreatic surgery can lead to severe surgical complications. Observation is somewhat contra-intuitive in oncology as both doctors and patients may fear that the time window to successfully treat the tumour can be missed. In this study the authors reported on a large group of patients. Patients in both groups had very good survival. Both strategies are reasonable and should be discussed with patients.
2022
Pancreatic cancer, Pancreatectomy, Pancreatic surgery
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1086005
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 4
social impact